Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease.

Horton MC, Nopoulos P, Nance M, Landwehrmyer GB, Barker RA, Squitieri F; REGISTRY Investigators of the European Huntington’s Disease Network, Burgunder JM, Quarrell O.

J Huntingtons Dis. 2019 Mar 7. doi: 10.3233/JHD-180306. [Epub ahead of print]

PMID:
30856116
2.

Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?

Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, Furby H, Saft C, Roos RAC, Squitieri F, Landwehrmeyer GB, Burgunder JM; Juvenile Huntington Disease Working Group of the European Huntington Disease Network.

Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27640. [Epub ahead of print] No abstract available.

PMID:
30788860
3.

CM-Pf deep brain stimulation and the long term management of motor and psychiatric symptoms in a case of Tourette syndrome.

Marano M, Migliore S, Squitieri F, Insola A, Scarnati E, Mazzone P.

J Clin Neurosci. 2019 Apr;62:269-272. doi: 10.1016/j.jocn.2018.12.029. Epub 2019 Jan 3.

PMID:
30612913
4.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
5.

DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease.

Castaldo I, De Rosa M, Romano A, Zuchegna C, Squitieri F, Mechelli R, Peluso S, Borrelli C, Del Mondo A, Salvatore E, Vescovi LA, Migliore S, De Michele G, Ristori G, Romano S, Avvedimento EV, Porcellini A.

Ann Neurol. 2019 Feb;85(2):296-301. doi: 10.1002/ana.25393. Epub 2019 Jan 13.

PMID:
30549309
6.

Effects of Stimulus-Related Variables on Mental States Recognition in Huntington'S Disease.

Belardinelli MO, Huenefeldt T, Maffi S, Squitieri F, Migliore S.

Int J Neurosci. 2018 Nov 27:1-21. doi: 10.1080/00207454.2018.1552691. [Epub ahead of print]

PMID:
30481084
7.

Emotional processing in RRMS patients: Dissociation between behavioural and neurophysiological response.

Migliore S, Curcio G, Porcaro C, Cottone C, Simonelli I, D'aurizio G, Landi D, Palmieri MG, Ghazaryan A, Squitieri F, Filippi MM, Vernieri F.

Mult Scler Relat Disord. 2019 Jan;27:344-349. doi: 10.1016/j.msard.2018.11.019. Epub 2018 Nov 19.

PMID:
30472414
8.

Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.

Fusilli C, Migliore S, Mazza T, Consoli F, De Luca A, Barbagallo G, Ciammola A, Gatto EM, Cesarini M, Etcheverry JL, Parisi V, Al-Oraimi M, Al-Harrasi S, Al-Salmi Q, Marano M, Vonsattel JG, Sabatini U, Landwehrmeyer GB, Squitieri F.

Lancet Neurol. 2018 Nov;17(11):986-993. doi: 10.1016/S1474-4422(18)30294-1. Epub 2018 Sep 19.

PMID:
30243861
9.

Task-switching abilities in pre-manifest Huntington's disease subjects.

Migliore S, D'Aurizio G, Curcio G, Squitieri F.

Parkinsonism Relat Disord. 2018 Sep 5. pii: S1353-8020(18)30392-4. doi: 10.1016/j.parkreldis.2018.09.007. [Epub ahead of print]

PMID:
30201420
10.

Optical coherence tomography (OCT) study in Argentinean Huntington's disease patients.

Gatto E, Parisi V, Persi G, Fernandez Rey E, Cesarini M, Luis Etcheverry J, Rivera P, Squitieri F.

Int J Neurosci. 2018 Dec;128(12):1157-1162. doi: 10.1080/00207454.2018.1489807. Epub 2018 Aug 21.

PMID:
29912591
11.

Generation of the induced pluripotent stem cell line CSSi006-A (3681) from a patient affected by advanced-stage Juvenile Onset Huntington's Disease.

Rotundo G, Bidollari E, Ferrari D, Spasari I, Bernardini L, Consoli F, De Luca A, Santimone I, Lamorte G, Migliore S, Squitieri F, Vescovi AL, Rosati J.

Stem Cell Res. 2018 May;29:174-178. doi: 10.1016/j.scr.2018.04.008. Epub 2018 Apr 21.

12.

Exploring emotion regulation and emotion recognition in people with presymptomatic Huntington's disease: The role of emotional awareness.

Zarotti N, Simpson J, Fletcher I, Squitieri F, Migliore S.

Neuropsychologia. 2018 Apr;112:1-9. doi: 10.1016/j.neuropsychologia.2018.02.030. Epub 2018 Mar 3.

PMID:
29510181
13.

Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington's disease at the presymptomatic stage.

Bidollari E, Rotundo G, Ferrari D, Candido O, Bernardini L, Consoli F, De Luca A, Santimone I, Lamorte G, Ilari A, Squitieri F, Vescovi AL, Rosati J.

Stem Cell Res. 2018 Apr;28:145-148. doi: 10.1016/j.scr.2018.02.014. Epub 2018 Feb 21.

14.

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub 2018 Feb 20.

PMID:
29460498
15.

Generation of induced pluripotent stem cell line, CSSi002-A (2851), from a patient with juvenile Huntington Disease.

Rosati J, Bidollari E, Rotundo G, Ferrari D, Torres B, Bernardini L, Consoli F, De Luca A, Santimone I, Lamorte G, Squitieri F, Vescovi AL.

Stem Cell Res. 2018 Mar;27:86-89. doi: 10.1016/j.scr.2018.01.011. Epub 2018 Jan 9.

16.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Apr;49:42-47. doi: 10.1016/j.parkreldis.2018.01.006. Epub 2018 Jan 5.

PMID:
29326033
17.

Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.

Cariulo C, Azzollini L, Verani M, Martufi P, Boggio R, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh JL, Conforti P, Cattaneo E, Santimone I, Squitieri F, Lashuel HA, Petricca L, Caricasole A.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10809-E10818. doi: 10.1073/pnas.1705372114. Epub 2017 Nov 21.

18.

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.

Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, Landi D, Palmieri MG, Moffa F, Filippi MM, Vernieri F.

Behav Neurol. 2017;2017:7404289. doi: 10.1155/2017/7404289. Epub 2017 Aug 15.

19.

Polyglutamine tracts regulate autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Autophagy. 2017 Sep 2;13(9):1613-1614. doi: 10.1080/15548627.2017.1336278. Epub 2017 Jul 19.

20.

Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.

Daldin M, Fodale V, Cariulo C, Azzollini L, Verani M, Martufi P, Spiezia MC, Deguire SM, Cherubini M, Macdonald D, Weiss A, Bresciani A, Vonsattel JG, Petricca L, Marsh JL, Gines S, Santimone I, Marano M, Lashuel HA, Squitieri F, Caricasole A.

Sci Rep. 2017 Jul 11;7(1):5070. doi: 10.1038/s41598-017-05336-7.

21.

Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.

Migliore S, Curcio G, Couyoumdjian A, Ghazaryan A, Landi D, Moffa F, Quintiliani L, Squitieri F, Palmieri MG, Filippi MM, Vernieri F.

Mult Scler. 2018 Sep;24(10):1328-1336. doi: 10.1177/1352458517719149. Epub 2017 Jul 5.

PMID:
28675956
22.

Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.

Sánchez-Castañeda C, de Pasquale F, Caravasso CF, Marano M, Maffi S, Migliore S, Sabatini U, Squitieri F.

CNS Neurosci Ther. 2017 Jun;23(6):488-497. doi: 10.1111/cns.12701. Epub 2017 May 2.

PMID:
28464463
23.

Polyglutamine tracts regulate beclin 1-dependent autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Nature. 2017 May 4;545(7652):108-111. doi: 10.1038/nature22078. Epub 2017 Apr 26.

24.

Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?

Morea V, Bidollari E, Colotti G, Fiorillo A, Rosati J, De Filippis L, Squitieri F, Ilari A.

Amino Acids. 2017 Jul;49(7):1147-1157. doi: 10.1007/s00726-017-2417-2. Epub 2017 Apr 10. Review.

PMID:
28396959
25.

Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Jankovic J, Squitieri F.

Neurology. 2017 Jan 17;88(3):334. doi: 10.1212/WNL.0000000000003527. No abstract available.

PMID:
28093514
26.

Early enteric neuron dysfunction in mouse and human Huntington disease.

Sciacca S, Favellato M, Madonna M, Metro D, Marano M, Squitieri F.

Parkinsonism Relat Disord. 2017 Jan;34:73-74. doi: 10.1016/j.parkreldis.2016.10.017. Epub 2016 Nov 1. No abstract available.

PMID:
27836713
27.

Major Superficial White Matter Abnormalities in Huntington's Disease.

Phillips OR, Joshi SH, Squitieri F, Sanchez-Castaneda C, Narr K, Shattuck DW, Caltagirone C, Sabatini U, Di Paola M.

Front Neurosci. 2016 May 23;10:197. doi: 10.3389/fnins.2016.00197. eCollection 2016.

28.

Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.

Luca G, Bellezza I, Arato I, Di Pardo A, Mancuso F, Calvitti M, Falabella G, Bartoli S, Maglione V, Amico E, Favellato M, Basta G, Bodo M, Minelli A, Calafiore R, Frati L, Squitieri F.

CNS Neurosci Ther. 2016 Aug;22(8):686-90. doi: 10.1111/cns.12569. Epub 2016 May 26.

PMID:
27225886
29.

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Squitieri F, de Yebenes JG.

Drug Des Devel Ther. 2015 Oct 28;9:5827-33. doi: 10.2147/DDDT.S65738. eCollection 2015.

30.

Juvenile Huntington disease in Argentina.

Gatto EM, Parisi V, Etcheverry JL, Sanguinetti A, Cordi L, Binelli A, Persi G, Squitieri F.

Arq Neuropsiquiatr. 2016 Jan;74(1):50-4. doi: 10.1590/0004-282X20150192. Epub 2015 Nov 24.

31.

Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease.

Tedroff J, Waters S, Barker RA, Roos R, Squitieri F; EHDN Registry Study Group.

J Huntingtons Dis. 2015;4(2):131-40. doi: 10.3233/JHD-150143.

PMID:
26397894
32.

Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.

Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR.

Mol Ther. 2015 Nov;23(11):1759-1771. doi: 10.1038/mt.2015.128. Epub 2015 Jul 23.

33.

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.

Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B.

Mov Disord. 2015 Sep;30(10):1426-9. doi: 10.1002/mds.26308. Epub 2015 Jul 14.

PMID:
26175332
34.

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.

Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L.

J Cell Mol Med. 2015 Nov;19(11):2540-8. doi: 10.1111/jcmm.12604. Epub 2015 Jun 22.

35.

Epidemiology of Huntington disease: first post-HTT gene analysis of prevalence in Italy.

Squitieri F, Griguoli A, Capelli G, Porcellini A, D'Alessio B.

Clin Genet. 2016 Mar;89(3):367-70. doi: 10.1111/cge.12574. Epub 2015 Mar 15.

PMID:
25689972
36.

Assessment Of The Huntington Quality Of Life Instrument (H-QOL-I) Cross-Cultural Validity.

Clay E, Belhadj A, Squitieri F, Dorey J, Auquier P, Zielonka D, Trigo P, Toumi M.

Value Health. 2014 Nov;17(7):A567. doi: 10.1016/j.jval.2014.08.1887. Epub 2014 Oct 26. No abstract available.

37.

Assessment Of The Huntington Clinical Self-Reported Instrument (H-CSRI) Cross-Cultural Validity.

Dorey J, Belhadj A, Squitieri F, Clay E, Auquier P, Zielonka D, Trigo P, Toumi M.

Value Health. 2014 Nov;17(7):A567. doi: 10.1016/j.jval.2014.08.1888. Epub 2014 Oct 26. No abstract available.

38.

Deep white matter in Huntington's disease.

Phillips O, Squitieri F, Sanchez-Castaneda C, Elifani F, Caltagirone C, Sabatini U, Di Paola M.

PLoS One. 2014 Oct 23;9(10):e109676. doi: 10.1371/journal.pone.0109676. eCollection 2014.

39.

The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study.

Sánchez-Castañeda C, Squitieri F, Di Paola M, Dayan M, Petrollini M, Sabatini U.

Hum Brain Mapp. 2015 Jan;36(1):50-66. doi: 10.1002/hbm.22612. Epub 2014 Aug 21.

PMID:
25145324
40.

MRI measures of corpus callosum iron and myelin in early Huntington's disease.

Di Paola M, Phillips OR, Sanchez-Castaneda C, Di Pardo A, Maglione V, Caltagirone C, Sabatini U, Squitieri F.

Hum Brain Mapp. 2014 Jul;35(7):3143-51. doi: 10.1002/hbm.22391. Epub 2013 Oct 15.

PMID:
24895252
41.

The Corticospinal Tract in Huntington's Disease.

Phillips O, Squitieri F, Sanchez-Castaneda C, Elifani F, Griguoli A, Maglione V, Caltagirone C, Sabatini U, Di Paola M.

Cereb Cortex. 2015 Sep;25(9):2670-82. doi: 10.1093/cercor/bhu065. Epub 2014 Apr 4.

PMID:
24706734
42.

Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene.

Alibardi A, Squitieri F, Fattapposta F, Missori P, Pierelli F, Trompetto C, Currà A.

Parkinsonism Relat Disord. 2014 Jun;20(6):678-9. doi: 10.1016/j.parkreldis.2014.03.007. Epub 2014 Mar 21. No abstract available.

PMID:
24698056
43.

Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Carrizzo A, Di Pardo A, Maglione V, Damato A, Amico E, Formisano L, Vecchione C, Squitieri F.

PLoS One. 2014 Feb 25;9(2):e89745. doi: 10.1371/journal.pone.0089745. eCollection 2014.

44.

Managing juvenile Huntington's disease.

Quarrell OW, Nance MA, Nopoulos P, Paulsen JS, Smith JA, Squitieri F.

Neurodegener Dis Manag. 2013 Jun 1;3(3). doi: 10.2217/nmt.13.18.

45.

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease.

Di Pardo A, Alberti S, Maglione V, Amico E, Cortes EP, Elifani F, Battaglia G, Busceti CL, Nicoletti F, Vonsattel JP, Squitieri F.

Mol Brain. 2013 Dec 13;6:55. doi: 10.1186/1756-6606-6-55.

46.

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.

Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, Maglione V.

Hum Mol Genet. 2014 May 1;23(9):2251-65. doi: 10.1093/hmg/ddt615. Epub 2013 Dec 2.

PMID:
24301680
47.

Tractography of the corpus callosum in Huntington's disease.

Phillips O, Sanchez-Castaneda C, Elifani F, Maglione V, Di Pardo A, Caltagirone C, Squitieri F, Sabatini U, Di Paola M.

PLoS One. 2013 Sep 3;8(9):e73280. doi: 10.1371/journal.pone.0073280. eCollection 2013.

48.

Neurodegenerative disease: 'fifty shades of grey' in the Huntington disease gene.

Squitieri F.

Nat Rev Neurol. 2013 Aug;9(8):421-2. doi: 10.1038/nrneurol.2013.128. Epub 2013 Jun 25. No abstract available.

PMID:
23797246
49.

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.

Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Neurogenetics. 2013 Nov;14(3-4):173-9. doi: 10.1007/s10048-013-0364-y. Epub 2013 May 4.

50.

One-year safety and tolerability profile of pridopidine in patients with Huntington disease.

Squitieri F, Landwehrmeyer B, Reilmann R, Rosser A, de Yebenes JG, Prang A, Ivkovic J, Bright J, Rembratt A.

Neurology. 2013 Mar 19;80(12):1086-94. doi: 10.1212/WNL.0b013e3182886965. Epub 2013 Feb 27.

PMID:
23446684

Supplemental Content

Loading ...
Support Center